<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01833819</url>
  </required_header>
  <id_info>
    <org_study_id>B.30.2.BAV.0.05.05/346</org_study_id>
    <nct_id>NCT01833819</nct_id>
  </id_info>
  <brief_title>Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy</brief_title>
  <official_title>Opioid-free Total Intravenous Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy; Comparison With Propofol, Remifentanil Infusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioids may attenuate postoperative hyperalgesia and postoperative nausea and vomiting. Our&#xD;
      hypothesis is: opioid-free total intravenous anesthesia with propofol, dexmedetomidine and&#xD;
      lidocaine infusions for laparoscopic cholecystectomy may achieve comparable hemodynamic&#xD;
      stability during laparoscopy, with lower postoperative analgesic consumption and incidence of&#xD;
      postoperative nausea and vomiting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomly allocated into two groups to have either opioid-free anesthesia (Group&#xD;
      DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg&#xD;
      loading, 2 mg/kg/h infusion), and propofol infusions or opioid-based anesthesia (Group RF)&#xD;
      with fentanyl, remifentanil (0.25μg/kg/min), and propofol infusions.&#xD;
&#xD;
      Simple randomization was done using 80 opaque sealed envelopes, 40 for each group, indicating&#xD;
      group assignment and describing the anesthetic protocol. Before anesthesia induction, an&#xD;
      anesthesiologist will open the next envelope in the sequence to reveal the treatment&#xD;
      allocation. This anesthesiologist will only prepare the study medications and will be&#xD;
      involved in neither preoperative and postoperative data collection nor anesthesia management&#xD;
      of the patients.&#xD;
&#xD;
      The drugs will be delivered in 10 ml and 50 ml syringes labeled as &quot;loading&quot; or &quot;infusion&quot;&#xD;
      respectively. To ensure proper blinding, the loading doses of drugs (dexmedetomidine and&#xD;
      lidocaine in Group DL or fentanyl and normal saline in Group RF) will be calculated according&#xD;
      to the patient's body weight and diluted to a 10 ml volume labeled as &quot;loading-1&quot; and&#xD;
      &quot;loading-2&quot; in order of administration. The infusion drugs (dexmedetomidine and lidocaine in&#xD;
      Group DL or remifentanil and normal saline in Group RF) will be prepared in 50 ml syringes&#xD;
      and labeled as &quot;infusion-1&quot; and &quot;infusion-2&quot; respectively.&#xD;
&#xD;
      At the preoperative holding area, patients will be instructed in the use of the verbal&#xD;
      numerical rating scale (VNRS) and patient controlled analgesia (PCA) pump. Same&#xD;
      anesthesiologist (MB) who is blinded to the study groups will perform the anesthesia&#xD;
      management of all procedures.&#xD;
&#xD;
      On arrival at the operating room, standard monitoring will be applied consisting of ECG,&#xD;
      noninvasive blood pressure, pulse oximetry and bispectral index (BIS). After premedication&#xD;
      with intravenous midazolam (0.03 mg/kg), baseline heart rate and mean arterial blood pressure&#xD;
      (MAP) will be determined which are average of three consecutive measurements. Preoxygenation&#xD;
      with 5 L/min of pure oxygen will be performed during administration of loading doses. Before&#xD;
      induction, patients in Group DL received 0.6 μg/kg dexmedetomidine (loading-1) diluted to a&#xD;
      total volume of 10 ml and infused in 10 minutes. To avoid bias, patients in Group RF will&#xD;
      receive 2 μg/kg fentanyl in same fashion. At the induction, dexmedetomidine or remifentanil&#xD;
      (1 μg/ml and 50 μg/ml respectively, infusion-1) infusions 0.3 ml/kg/h will be started and&#xD;
      lidocaine 1.5 mg/kg (loading-2) in Group DL or normal saline in Group RF and propofol 1.5&#xD;
      mg/kg will be administered. Lidocaine (20 mg/ml) or normal saline infusions 0.1 ml/kg/h and&#xD;
      propofol infusion 10 mg/kg/h will be started immediately after loading doses. Vecuronium 0.1&#xD;
      mg/kg i.v. will be given to facilitate tracheal intubation.&#xD;
&#xD;
      The lungs will be mechanically ventilated with a mixture of oxygen in air (FiO2: 50%, tidal&#xD;
      volume 7-10 ml/kg, respiratory rate 10-14/min) to obtain an end-tidal CO2 (EtCO2) value&#xD;
      between 30-35 mmHg. Supplemental neuromuscular blockade will be achieved with vecuronium&#xD;
      after assessment of neuromuscular function with train-of-four.&#xD;
&#xD;
      Dexmedetomidine and lidocaine infusions in Group DL or remifentanil and normal saline&#xD;
      infusions in Group RF will kept constant during surgery. Propofol infusion rate will be&#xD;
      adjusted 3-12 mg/kg/h to maintain the MAP within ±20% of the baseline value, and to maintain&#xD;
      a BIS reading below 50. The lidocaine or normal saline administration will be terminated&#xD;
      after gallbladder extraction (or 10 min before the end of surgery). Dexmedetomidine or&#xD;
      remifentanil and propofol administration will be terminated during skin closure.&#xD;
&#xD;
      All patients in both groups will receive 8 mg dexamethasone and 50 mg dexketoprofen&#xD;
      trometamol i.v. after anesthesia induction and 1 g paracetamol i.v. after gallbladder&#xD;
      extraction. Laparoscopic portals will be infiltrated with 20 ml 0.5% bupivacaine including&#xD;
      1/80.000 adrenaline before skin closure.&#xD;
&#xD;
      Surgery: Surgeons who are experienced in laparoscopic cholecystectomy will performed the&#xD;
      operations using standard 4-trocar technique. A blunt-tipped 12-mm trocar will be used to&#xD;
      access the peritoneal cavity. Pneumoperitoneum will be achieved with carbon dioxide, and&#xD;
      intra-abdominal pressure will be maintained at 12-14 mmHg throughout surgery. Three&#xD;
      additional 5-mm ports will be introduced and patients will be positioned in 30 degrees&#xD;
      anti-Trendelenburg position and be rotated toward the left side to facilitate exposure of the&#xD;
      gallbladder. After endotracheal intubation a nasogastric tube will be inserted and stomach&#xD;
      content will be aspirated. At the end of surgery, the inflated carbon dioxide will carefully&#xD;
      be evacuated by manuel compression of the abdomen.&#xD;
&#xD;
      A PCA pump will be ready to use immediately after extubation. The PCA pump will set to&#xD;
      deliver fentanyl i.v. with a bolus dose of 20 μg, a lock-out of 5 min, without continuous&#xD;
      infusion and dose limit for 6 hours after surgery. Trained nurses, blinded to treatment&#xD;
      allocation and with no access to the intraoperative records, will perform all outcome&#xD;
      assessments in the postanesthesia care unit (PACU) and surgical ward. Pain scores will be&#xD;
      assessed using the 11-point VNRS (0 corresponding to no pain and 10 to the worst imaginable&#xD;
      pain).&#xD;
&#xD;
      Transition from PACU to surgical ward will be considered to be safe when patient will&#xD;
      achieved a Modified Aldrete Score ≥ 9. Although laparoscopic cholecystectomy is established&#xD;
      as a day-case procedure, our protocol is designed to admit all patients for 24 h to ensure&#xD;
      adequate follow-up of patients and for proper data collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative fentanyl consumption</measure>
    <time_frame>6 hours after extubation</time_frame>
    <description>Patients will use a Patient controlled analgesia (PCA) device for 6 hours after extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>2 hours after cessation of anesthesia infusions</time_frame>
    <description>Extubation time after cessation of anesthesia infusions and discharge time from postanesthesia care unit (PACU) after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>Postoperative 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Opiod-free group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid-based group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine and lidocaine</intervention_name>
    <arm_group_label>Opiod-free group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <arm_group_label>Opioid-based group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists I-II patients&#xD;
&#xD;
          -  20-60 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists III and above patients&#xD;
&#xD;
          -  BMI: 35 and above&#xD;
&#xD;
          -  Hepatic, renal or cardiac insufficiency&#xD;
&#xD;
          -  2 degree Heart block and above&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  History of chronic pain&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Allergy to any of a drug in the study groups&#xD;
&#xD;
          -  Pregnant, breast-feeding or menstruating women&#xD;
&#xD;
          -  Inability to use a patient-controlled analgesia device&#xD;
&#xD;
          -  Any analgesic or antiemetic use in last 24 hours before anesthesia induction&#xD;
&#xD;
          -  Any surgical complication that may affect the outcomes of the study (open surgery&#xD;
             etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bezmialem Vakif University Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2013</study_first_posted>
  <last_update_submitted>November 12, 2013</last_update_submitted>
  <last_update_submitted_qc>November 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laparoscopic cholecystectomy,</keyword>
  <keyword>Total intravenous anesthesia,</keyword>
  <keyword>Propofol,</keyword>
  <keyword>Dexmedetomidine,</keyword>
  <keyword>Lidocaine,</keyword>
  <keyword>Remifentanil,</keyword>
  <keyword>Postoperative analgesic consumption,</keyword>
  <keyword>Postoperative nausea and vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

